 CHARLOTTESVILLE, VA ACCESSWIRE February 6, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder AUD. The trial has initially started in Finland, where Adial previously announced it had received approval to commence the trial. Adial has filed clinical trial applications CTAs to also conduct the trial in each of these countries where additional trial sites will be initiated on a country-by-country basis following each CTA approval. 